Cancer drug licensed by GSK from China posts promising trial results
葛兰素史克从manbetx3.0
药企获得许可的抗癌药物公布积极的试验结果
Mo-Rez, developed by Hansoh Pharma, is a next-generation treatment for ovarian and endometrial cancer
由翰森制药开发的Mo-Rez是治疗卵巢癌和子宫内膜癌的新一代疗法。
A cancer drug licensed by GSK from China has delivered promising results in a trial, in a boost for the company’s oncology strategy.
葛兰素史克(GSK)从manbetx3.0
获得许可的一款抗癌药在一项试验中取得了可喜的结果，对该公司的肿瘤学战略是一大利好。
您已阅读4%（186字），剩余96%（4430字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。